A Stable Pep2-proapoptotic Peptide Inducing Apoptosis of Acute Myeloid Leukemia Cells by Down-Regulating EZH2
- 4 December 2019
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Bioengineering
- Vol. 13 (2) , 165-177
Abstract
Introduction Proapoptotic peptide, (KLAKLAK)2, exhibits strong anti-tumor effect with the help of cell-penetrating peptides such as Pep2, targeting TLR2 with high expression in acute myeloid leukemia (AML). However, the applications are limited due to the peptide’s instability and high cost of synthesis. Recombinant PP7 bacteriophage-like particles (VLPs) can protect the peptides from degradation by proteases, based on their ability to display foreign peptides. Methods Here, we evaluated the feasibility of PP7 VLPs carrying Pep2 and (KLAKLAK)2 (2PP7-Pep2-KLAK VLPs) expressed in E. coli. We further investigated the characteristics including size, toxicity, thermal stability, penetrating ability, anti-tumor activity, and potential anti-tumor mechanism of 2PP7-Pep2-KLAK VLPs. Results 2PP7-Pep2-KLAK VLPs was expressed in E. coli BL21(DE3) successfully with high yield and thermal stability. They penetrated the AML cells THP-1 rapidly after 30 min of incubation. Moreover, 2PP7-Pep2-KLAK VLPs were non-replicative, non-infectious, and non-toxic against normal cells, but inhibited the proliferation of THP-1 cells by inducing cell apoptosis after 24 h of exposure. This effect extends through 120 h of exposure, indicating their anti-proliferation effect was superior to that of synthetic peptides. In addition to the mitochondrial apoptotic pathway, the anti-tumor activity of 2PP7-Pep2-KLAK VLPs was also correlated with down-regulation of expression of enhancer of zeste homolog 2 (EZH2) and trimethylation of histone H3K27. Conclusions We identified the feasibility to prepare the stable, active Pep2-KLAK peptide by using PP7 bacteriophage as the vehicle. We revealed this peptide was an inhibitor of EZH2. 2PP7-Pep2-KLAK VLPs may have significant clinical implications in the treatment of MLL-AF9 AML as an epigenetic modulator.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (ZR2015HL036, ZR2019BH009)
- Shandong Provincial Education Science Plan (J14LK14)
- National Natural Science Foundation of China (81570157, 81700167)
- Innovative Research Group Project of the National Natural Science Foundation of China (81770915)
This publication has 24 references indexed in Scilit:
- VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human PapillomavirusPLOS ONE, 2012
- Polycomb repressive complex 2 is required for MLL-AF9 leukemiaProceedings of the National Academy of Sciences, 2012
- Bicinchoninic acid (BCA) assay in low volumeAnalytical Biochemistry, 2011
- Thermal Stability of RNA Phage Virus-Like Particles Displaying Foreign PeptidesJournal of Nanobiotechnology, 2011
- TLR2 engagement on memory CD8+ T cells improves their cytokine‐mediated proliferation and IFN‐γ secretion in the absence of AgEuropean Journal of Immunology, 2009
- A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDSBlood, 2009
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Immunogenic Display of Diverse Peptides on Virus-like Particles of RNA Phage MS2Journal of Molecular Biology, 2008
- Selective Apoptotic Killing of Malignant Hemopoietic Cells by Antibody-Targeted Delivery of an Amphipathic PeptideCancer Research, 2005
- De Novo Antimicrobial Peptides with Low Mammalian Cell ToxicityJournal of Medicinal Chemistry, 1996